GlobeNewswire by notified

Saniona Initiates Positron Emission Tomography (PET) Stage of SAN711 Phase 1 Clinical Trial

Share

PRESS RELEASE

March24, 2022

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has initiated the positron emission tomography (PET) stage of its Phase 1 clinical trial of SAN711. SAN711 isa potential first-in-class GABA-A α3 ion channel modulator that may be applicable in treating pain and neuropathic disorders. The ongoing Phase 1 trial is placebo-controlled, and the data remain blinded. Saniona continues to expect data from the trialby the end of the first half of 2022.

“We are excited to initiate the third and final stage of this Phase 1 clinical trial of SAN711. PET evaluations will provide data indicating how well SAN711 binds to GABA-A receptors in the central nervous system. This is particularly important because SAN711 is a potentially first-in-class GABA-A α3 selective positive allosteric modulator, which we believe may ultimately avoid the off-target effects of less selective GABA-A modulators,” said Rudolf Baumgartner, M.D., Chief Medical Officer and Head of Clinical Development at Saniona​.

The Phase 1 clinical trial is a randomized, placebo-controlled study being conducted in approximately 80 healthy volunteers. The primary objective of the study is to determine the tolerability and the maximum tolerated dose of SAN711, as evaluated through the single ascending dose and multiple ascending dose phases of the study. The secondary objective is to measure binding to target receptors, as assessed during a positron emission tomography (PET) evaluation phase of the study. More information is available at www.clinicaltrials.gov.

SAN711 is an investigational, potential first-in-class positive allosteric modulator of GABA-A α3 receptors. GABA is a neurotransmitter, or chemical messenger, that inhibits signals between nerve cells in the brain. Inhibiting these signals can result in outcomes such as sedation, pain relief, itch relief or seizure inhibition. By selectively activating α3 GABA-A receptors, SAN711 may have the potential to restore spinal inhibitory tone and prevent abnormal pain signaling to the brain. Preclinical studies have indicated that because SAN711 only activates α3 GABA-A receptors, this selectivity may allow SAN711 to provide pain relief and other benefits in the central nervous system while avoiding the typical adverse effects associated with non-selective GABA-A activation such as sedation, motor instability, cognitive impairment, abuse liability and physical dependence. SAN711 is the first novel molecule derived from Saniona’s proprietary ion channel drug discovery engine to be advanced into internal clinical trials.

For more information, please contact
Trista Morrison, Chief Corporate Affairs Officer, Saniona. Office: + 1 (781) 810-9227. Email: trista.morrison@saniona.com

The information was submitted for publication, through the agency of the contact person set out above, at 8:00 CET on 24March 2022.

About Saniona
Saniona is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for patients suffering from rare diseases for which there are a lack of available treatment options. The company’s lead product candidate, Tesomet™, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, serious rare disorders characterized by severe weight gain, disturbances of metabolic functions and uncontrollable hunger. Saniona has developed a proprietary ion channel drug discovery engine anchored by IONBASE™, a database of more than 130,000 compounds, of which more than 20,000 are Saniona’s proprietary ion channel modulators. Through its ion channel expertise, Saniona is advancing two wholly-owned ion channel modulators, SAN711 and SAN903. SAN711 is in a Phase 1 clinical trial and may be applicable in the treatment of rare neuropathic disorders, and SAN903 is in preclinical development for rare inflammatory, fibrotic and hematological disorders. Led by an experienced scientific and operational team, Saniona has an established research organization in the Copenhagen area, Denmark, and a corporate office in the Boston, Massachusetts area, U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at http://www.saniona.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Game studio Omnigame picks Agillic to scale personalisation and international growth16.5.2022 10:30:00 CEST | Press release

Press release, Copenhagen, 16 May 2022 OmnigameApS is an independent Danish online game studio on an ambitious mission to deliver quality, highly entertaining games and boost player engagement through its new communication strategy. Uncompromising on quality in both their games and customer experience, Omnigame turned to Agillic for operational efficiency, empowering its team to turn its copious data into highly personalised and relevant communication, and to scale the business internationally without ballooning headcounts. With implementation by Agillic Gold Solution Partner NexusOne, Omnigame was up and running on Agillic in less than three months. Since April, it has been leveraging the platform to run automated customer journeys, using content, personalisation and language versions dynamically across three owned channels - with room to scale. Omnigame’s Head of CX, Pia Nørland, says: ‘We are really excited to have started with Agillic. With the first flows already in place and runn

Stockwik förvärvar Cordinator Medical Service16.5.2022 10:00:00 CEST | Pressemelding

Solna den 16 maj 2022 PRESSMEDDELANDE Stockwik Förvaltning AB (publ) har ingått avtal om förvärv av Cordinator Medical Service AB (”Cordinator”). Stockwik förvärvar samtliga aktier i Cordinator. Som ett av Östergötlands ledande företag inom sitt verksamhetsområde företagshälsovård och privat sjukvård kompletterar Cordinator på ett utmärkt sätt Stockwiks övriga företag inom segmentet; TEAM Hälsa, Hela Företagshälsovård, Tjugonde Friskvård och Hälsobolaget. Med Cordinators verksamhet i Linköping och Norrköping täcker vi nu en stor del av Sverige. På Cordinators kliniker finns idag ca 30 anställda och konsulter. Verksamheten har bedrivits av Gunilla Rundqvist sedan 2004 med fokus på kvalitet och kundnöjdhet. För den senaste tolvmånadersperioden, per den 30 april 2022, uppgick Cordinators nettoomsättning till 26 MSEK. EBITDA-resultatet uppgick för motsvarande period till knappa 4 MSEK. Transaktionen sker på skuldfri basis till en EBITDA-multipel 6x. BAKGRUND OCH MOTIV Förvärvet av Cordinat

Grayscale Investments® Launches First European ETF: Grayscale Future of Finance UCITS ETF16.5.2022 09:00:00 CEST | Press release

Grayscale Future of Finance UCITS ETF (ticker: GFOF) listed on select exchanges across Europe Grayscale’s first European ETF accelerates its global strategic expansion NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Grayscale Investments®, the world’s largest digital currency asset manager, today announced its first European ETF, Grayscale Future of Finance UCITS ETF (ticker: GFOF), will list on the London Stock Exchange (LSE), Borsa Italiana, and Deutsche Börse Xetra. GFOF UCITS ETF will also be passported for sale across Europe. GFOF UCITS ETF tracks the investment performance of the Bloomberg Grayscale Future of Finance Index and seeks to offer investors exposure to companies at the intersection of finance, technology, and digital assets – companies that are building the digital economy – all through the familiar ETF wrapper. In February 2022, Grayscale listed an ETF in the United States that tracks the investment performance of the Bloomberg Grayscale Future of Finance Index. The Bloomb

Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme16.5.2022 08:45:00 CEST | Press release

Company Announcement No. 33/2022 Copenhagen, 16 May 2022 Transactions in connection with share buy-back programme On 9 March 2022, Scandinavian Tobacco Group A/S (“STG”) announced that a share buy-back programme of an aggregated price of up to DKK 700 million was launched with the purpose to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. The buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. The share buy-back programme will end no later than 28 February 2023. The following transactions have been executed from 9 May to 12 May 2022: Number of sharesAverage purchase price, DKKTransaction value, DKKAccumulated, last announcement737,564104,827,453 9 May 202222,530147.253,317,65110 May 202220,250151.163,061,06311 May 2